Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN727 add-on therapy versus placebo in heterozygous familial hypercholesterolemia
NL-OMON39622Phase 3Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of alirocumab, sponsored by Regeneron Pharmaceuticals. Started Dec 2012; status: active, not recruiting.
02
Drugs
alirocumab
Beyond the preview
Go deeper on NL-OMON39622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39622.